MediPharm Labs Corp. LABS.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 100.11% | -134.33% | -14.49% | 23.53% | -44.34% |
| Total Depreciation and Amortization | -8.39% | -5.94% | -29.12% | -19.72% | -43.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.34% | -22.83% | 138.47% | -73.16% | -62.65% |
| Change in Net Operating Assets | -536.93% | 81.68% | 111.58% | 54.53% | 146.79% |
| Cash from Operations | 84.33% | 71.38% | 140.93% | 76.37% | -70.51% |
| Capital Expenditure | -9.21% | 97.61% | 100.00% | 52.07% | 25.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 19,952.94% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -101.09% | 97.61% | 100.00% | 1,477.27% | 11,966.41% |
| Total Debt Issued | -8.60% | -- | -- | -100.00% | -33.24% |
| Total Debt Repaid | 35.71% | 30.57% | 33.83% | 94.76% | 45.10% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 22.58% | -17.86% | -49.37% | 135.00% | -65.17% |
| Cash from Financing | -1.39% | 30.91% | 24.67% | 96.75% | -35.46% |
| Foreign Exchange rate Adjustments | -39.64% | 51.35% | 36.01% | -133.33% | 79.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.84% | 69.71% | 115.90% | 107.58% | 302.99% |